An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
NCT03779113
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
69
Enrollment
INDUSTRY
Sponsor class
Stopped
Study terminated by sponsor
Conditions
Non Hodgkin Lymphoma
Interventions
DRUG:
HMPL-523
Sponsor
Hutchmed